Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 21;12(5):5846–5858. doi: 10.1002/cam4.5372

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

The response rate was higher in patients with high ratio of CD8 to CD163. (A) Representative images from mIHC analysis of CD8 T cell marker (CD8: blue) and M2 macrophage marker (CD163: red). (B) Distribution of CD8 and CD163 from 21 TNBC patients. (C–D) Comparison of CD8 (C) and CD163 (D) between responders and non‐responders. (E) Barplots of pCR rate and MP5 grade rate between CD8‐H group and CD8‐L group. (F) Barplots of pCR rate and MP5 grade rate between CD163‐H group and CD163‐L group. (G) Comparison of CD8/CD163 between responders and non‐responders. (H) Barplots of pCR rate and MP5 grade rate between CD8/CD163H group and CD8/CD163‐L group.